Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.870 -0.060 (-1.01%)
Streaming Delayed Price Updated: 1:07 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
 
Via Benzinga
News headline image
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Vir Biotechnology ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Vir Biotechnology ↗
 
Via Benzinga
News headline image
7 Analysts Have This To Say About Vir Biotechnology ↗
 
Via Benzinga
News headline image
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment ↗
The company is working to engage the immune system to attack cancer cells. 
Via Investor's Business Daily
News headline image
Vir (VIR) Q2 Revenue Drops 61% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Where Vir Biotechnology Stands With Analysts ↗
 
Via Benzinga
News headline image
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why ↗
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why ↗
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies. 
Via Benzinga
News headline image
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
News headline image
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? ↗
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.